← Back to Search

Cancer Preventive Agent

Green Tea for Prostate Cancer

Phase 2
Recruiting
Led By Nagi B Kumar
Research Sponsored by ECOG-ACRIN Cancer Research Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months

Summary

This trial looks at whether green tea catechins can prevent prostate cancer from progressing in men who are being closely monitored for the disease.

Who is the study for?
Men with low to intermediate-risk prostate cancer under active surveillance can join. They must have a recent biopsy showing adenocarcinoma, be in good physical condition (ECOG 0-1), and agree to stop taking their own supplements for the study's version. HIV-positive men on effective treatment are eligible. Participants need normal organ function tests, agree to limit tea intake, use contraception if sexually active, and commit to follow-up biopsies.
What is being tested?
This phase II trial is testing whether green tea catechins can prevent prostate cancer from advancing in stages among men who are monitoring their condition without immediate treatment. The study involves taking either the green tea extract or a placebo and completing questionnaires about quality of life.
What are the potential side effects?
While not explicitly listed in the provided information, potential side effects may include digestive issues due to green tea extracts such as stomach upset or constipation, and possible allergic reactions for those sensitive to components of green tea.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in the highest percent Ki-67 expression
Secondary study objectives
Apoptosis
Apoptosis ratio
Change in geometric mean of percent Ki-67
+6 more
Other study objectives
Changes in lower urinary tract symptoms
Changes in lower urinary tract symptoms (LUTS)
Changes in quality of life (QOL)
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Arm A (green tea catechins)Experimental Treatment3 Interventions
Patients receive green tea catechins PO BID for up to 6 months in the absence of disease progression or unacceptable toxicity.
Group II: Arm B (placebo)Placebo Group3 Interventions
Patients receive placebo PO BID for up to 6 months.

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,956 Previous Clinical Trials
41,111,871 Total Patients Enrolled
516 Trials studying Prostate Cancer
332,960 Patients Enrolled for Prostate Cancer
ECOG-ACRIN Cancer Research GroupLead Sponsor
121 Previous Clinical Trials
179,837 Total Patients Enrolled
2 Trials studying Prostate Cancer
683 Patients Enrolled for Prostate Cancer
Nagi B KumarPrincipal InvestigatorECOG-ACRIN Cancer Research Group

Media Library

Green Tea (Cancer Preventive Agent) Clinical Trial Eligibility Overview. Trial Name: NCT04597359 — Phase 2
Prostate Cancer Research Study Groups: Arm A (green tea catechins), Arm B (placebo)
Prostate Cancer Clinical Trial 2023: Green Tea Highlights & Side Effects. Trial Name: NCT04597359 — Phase 2
Green Tea (Cancer Preventive Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04597359 — Phase 2
Prostate Cancer Patient Testimony for trial: Trial Name: NCT04597359 — Phase 2
~240 spots leftby Dec 2032